ROSEN, TRUSTED INVESTOR COUNSEL, Encourages Soleno Therapeutics, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action – SLNO

Core Viewpoint - Rosen Law Firm is reminding investors who purchased common stock of Soleno Therapeutics, Inc. during the specified Class Period of the upcoming lead plaintiff deadline on May 5, 2026 [1] Group 1: Class Action Details - Investors who bought Soleno common stock between March 26, 2025, and November 4, 2025, may be eligible for compensation without any out-of-pocket fees through a contingency fee arrangement [2] - A class action lawsuit has already been filed, and interested parties can join by contacting Rosen Law Firm [3][6] - To serve as lead plaintiff, individuals must file a motion with the Court by May 5, 2026 [3] Group 2: Legal Representation - Rosen Law Firm emphasizes the importance of selecting qualified legal counsel with a proven track record in securities class actions [4] - The firm has achieved significant settlements, including the largest securities class action settlement against a Chinese company, and has consistently ranked highly in securities class action settlements [4] Group 3: Case Allegations - The lawsuit alleges that Soleno made false or misleading statements regarding the safety of its Phase 3 clinical trial program for diazoxide choline extended-release tablets (DCCR) [5] - Specific concerns include downplaying safety risks related to excess fluid retention and the overall commercial viability of DCCR, which may lead to adverse events post-launch [5]